Eur Radiol: What is the total survival rate of liver cancer after arterial chemotherapy embolism, which affects the liver veins or lower cavity veins?

Objective: No effective treatment has been established for hepatocellular carcinoma (HCC) that invades the liver vein (HV) or the lower cavity vein (IVC).
study aims to determine the therapeutic effect of hepatic arterial chemotherapy embolism (TACE) on HCC patients with HV or IVC attacks, and to establish a risk prediction model.
: A retrospective analysis of data from patients who received TACE as a first-line treatment for liver cancer-infringing HIV or IVC between 1997 and 2019.
: The study included data on 296 patients (data from 1997-2006 to form a training queue, n s 174; Data for 2007-2019 make up the validation queue, n s 122).
the median survival time of patients after TACY was 7.3 months, and objective expected results were achieved in 34.1% of patients.
multivariate Cox analysis of the training queue identified five pre-treatment factors (maximum tumor size of 10 cm, immersion HCC, combined gate vein immersion, liver metastasis, and ECOG performance status1), which can be used to create predictive models of total survival.
low risk group (risk sum: 0-3) and high risk group (risk sum: 4-7) have a median total survival time of 14 and 4.2 months in the validation queue, respectively.
the time-dependent ROC curve applied to the total survival prediction model of the validation queue shows acceptable AUC values (0.723 and 0.667 at 6 months and 1 year, respectively).
: TACE is effective in liver cancer patients who partially violate HIV or IVC.
predictive model helps to screen patients who are treated with TACE.